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OBJECTIVE
The Diabetes Control and Complications Trial (DCCT) demonstrated the beneﬁcial
effects of intensive versus conventional therapy on the development and progres-
sion of microvascular complications of type 1 diabetes. These beneﬁcial effects
were almost completely explained by the difference between groups in the levels
of HbA1c, which in turn were associated with the risk of these complications. We
assessed the association of glucose variability within and between quarterly
7-point glucose proﬁles with the development and progression of retinopathy,
nephropathy, and cardiovascular autonomic neuropathy during the DCCT.
RESEARCH DESIGN AND METHODS
Measures of variability included the within-day and updated mean (over time) of
the SD, mean amplitude of glycemic excursions (MAGE), and M-value, and the
longitudinal within-day, between-day, and total variances. Imputation methods
ﬁlled in the 16.3% of expected glucose values that were missing.
RESULTS
Cox proportional hazards models assessed the association of each measure of
glycemic variation, as a time-dependent covariate, with the risk of retinopathy
and nephropathy, and a longitudinal logistic regression model did likewise for
cardiovascular autonomic neuropathy. Adjusted for mean blood glucose, no mea-
sure of within-day variability was associated with any outcome. Only
the longitudinal mean M-value (over time) was signiﬁcantly associated with
microalbuminuria when adjusted for the longitudinal mean blood glucose and
corrected for multiple tests using the Holm procedure.
CONCLUSIONS
Overall, within-day glycemic variability, as determined from quarterly glucose
proﬁles, does not play an apparent role in the development of microvascular
complications beyond the inﬂuence of the mean glucose.
TheDiabetes Control and Complications Trial (DCCT) (1) demonstrated that 6.5 years
of intensive therapy markedly reduced the risks of the onset and progression of
the microvascular complications of type 1 diabetes (retinopathy and nephropa-
thy) and neuropathy. Subsequent analyses showed that the lifetime exposure to
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hyperglycemia, represented by themean
HbA1c, was the dominant determinant of
the risk of complications (2), with no
threshold or breakpoint above the nor-
mal range (3). Further, virtually all of the
beneﬁcial effects of intensive therapy
were explained by the differences
in mean levels of HbA1c during the
trial (4).
Brownlee and Hirsch (5) previously
postulated that glycemic variables other
than HbA1c may contribute to diabetes
complications. They speciﬁcally com-
mented on a mechanistic article by
Monnier et al. (6) that presented a case-
control study in which markers of oxida-
tive stress (free radical production) were
compared with the mean amplitude of
glucose excursions (MAGE) of Service
et al. (7) and to the mean glucose level
obtained from continuous blood glucose
monitoring. Monnier et al. (6) showed
that the MAGE, but not the mean level
of glucose, was associated with free rad-
ical production. Brownlee and Hirsch
conjectured that an additional feature of
hyperglycemia not represented by the
HbA1c determines the risk of complica-
tions, speciﬁcally the degree of variability
in blood glucose.
Kilpatrick et al. (8), with accompany-
ing commentary (9), used the publically
available DCCT data to show that the
within-day variability in blood glucose,
expressed as the SD of the 7-point blood
glucose proﬁle, was not signiﬁcantly as-
sociated with the progression of reti-
nopathy or nephropathy when added to
the effect of themean glucose level. How-
ever, the incompleteness of the glucose
proﬁles calls into question the robustness
of the observations and conclusions by
Kilpatrick et al.
Service and O’Brien (10) avoided this
pitfall by restricting their analysis to the
7-point glucose proﬁles of 565 of 1,441
DCCT participants, who were monitored
for more than 4 years and had more than
80% of their glucose proﬁles complete.
They observed no association among var-
ious measures of within-day glucose var-
iability (SD,MAGE, orM-value) during the
DCCT with the onset and progression of
retinopathy. However, the restricted
sample size potentially affects the power
of these analyses.
Kilpatrick and colleagues also reported
that within-day variability in blood glu-
cose represented by the SD and MAGE
was not associated with progression of
retinopathy or nephropathy (11), neu-
ropathy (12), or cardiovascular events
during DCCT (13) when adjusted for the
mean glucose level; however, longitudi-
nal variability in HbA1c was associated
with progression of microvascular com-
plications during the DCCT (14). They
also showed that within-day variability
in blood glucose was an independent
risk factor for hypoglycemia (15).
Overall compliance in the DCCT was
high; however, completion of the 7-point
proﬁle collections was problematic,
with many missing data points. DCCT/
Epidemiology of Diabetes Interventions
and Complications (EDIC) researchers
(16) recently addressed this limitation
by applying amodern computer-intensive
statistical method, multiple imputation,
to estimate missing blood glucose proﬁle
values based on other measurements
that were observed, greatly increasing
the statistical validity of the analyses. Us-
ing thesemethods, we recently evaluated
the association of the within-day mean
blood glucose and its components with
glycated albumin and HbA1c, and the as-
sociation of each with hypoglycemia and
microvascular outcomes in DCCT (16).
However, measures of long-term glycemic
variabilitywerenot explored.Wenowpre-
sent analyses of the effects over time of
the mean level of glycemia, and of mea-
surements of variability of blood glucose,
using multiple imputation methods to
complete the glucose proﬁles, on the risk
of development and progression of reti-
nopathy, nephropathy, and cardiovascular
autonomic neuropathy (CAN).
RESEARCH DESIGN AND METHODS
Patients
The DCCT enrolled 1,441 subjects with
type 1 diabetes, with 711 randomly
assigned to intensive therapy aimed at
achieving levels of glycemia (HbA1c) as
close to the nondiabetic level as safely
possible and 730 assigned to conven-
tional therapy aimed at maintaining
clinical well-being with no speciﬁc glu-
cose targets (1). Two subcohorts
were enrolled: a primary prevention
cohort of 726 patients with 1–5 years’
duration of diabetes, no retinopa-
thy, and an albumin excretion rate
(AER) ,40 mg/24 h on study entry;
and a secondary intervention cohort
of 715 patients with 1–15 years of di-
abetes, minimal to moderate retinopa-
thy, and AER ,200 mg/24 h.
Measurements
These analyses are based on the mea-
sures of glycemia and the development
and progression of complications during
the DCCT (1983–1993).
Fundus photographs were obtained
every 6 months during the DCCT, from
which the severity of retinopathy for
each subject was centrally graded
according to the Early Treatment Dia-
betic Retinopathy Study (ETDRS) scale
(17). Retinopathy progression was de-
ﬁned as a sustained progression of
three or more steps from the level at
baseline observed on two successive
6-month visits. The AER was measured
annually from a timed urine collection
during the DCCT. Onset of microalbu-
minuria was deﬁned as an AER $30
mg/24 h on two successive visits among
the 1,284 (1,4412157) with an AER,30
mg/24 h at baseline (1).
The presence of CANwas evaluated at
DCCT baseline and every 2 years during
DCCT using cardiovascular autonomic
reﬂex tests that assessed the R-R re-
sponse to paced breathing (R-R varia-
tion), the Valsalva maneuver, and
postural changes in blood pressure (18).
CANwas deﬁned as an R-R variation,15,
or an R-R variation 15–19.9 combined
with a Valsalva ratio #1.5, or a decrease
of.10 mmHg in diastolic blood pressure
after standing for 10 min. The 66 subjects
with CAN at baseline were excluded from
these analyses.
HbA1c was measured in all patients
quarterly, from which a longitudinal
mean HbA1c value was computed at
each 6-month visit. Quarterly, a 7-point
capillary blood glucose proﬁle (Proﬁlsets;
Boehringer-Mannheim Diagnostics, Indi-
anapolis, IN) was collected by the partic-
ipants at home with samples collected
before and 90 min after each meal and
at bedtime. The samples were collected
in capillary tubes, placed in diluent, and
shipped to the DCCT Central Biochemis-
try Laboratory at the University of
Minnesota, where the hemolysates were
analyzed for glucose as previously
described (1).
In addition to mean blood glucose,
three well established metrics of glu-
cose variability that differed in charac-
terization of glycemic behavior were
computed from each quarterly proﬁle: 1)
SD, an expression of variability in glu-
cose exposure; 2) MAGE (7), a measure
of glucose excursions reﬂecting glycemic
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variability independent of glucose expo-
sure; and 3) M-value of Schlichtkrull et al.
(19), as modiﬁed (10), a hybrid of glucose
exposure and glycemic variability. The
MAGE was originally developed for use
with continuous in vivo blood glucose
analysis using an autoanalyser that pre-
ceded continuous glucose monitoring
(CGM). Its value is provided by an algo-
rithm, not a single equation. The MAGE
values reported here were computed
using a program provided by Service
and O’Brien (10) for application to
7-point blood glucose proﬁles as used in
their prior report. Our computations of
the M-value used a reference blood glu-
cose value of 90 mg/dL, which reﬂects
mean nondiabetic glycemia usingmodern
methodology.
In addition to the values at each visit,
the longitudinal mean of each measure
was computed from all prior visit proﬁle
values up to each 6-month visit (e.g., the
mean of the within-day MAGE up to
6 months, then up to 12 months, etc.).
The longitudinal variances of the glu-
cose values within and between proﬁles
and the longitudinal total variance of all
glucose values were also computed up
to each 6-month visit. These between-
day or longitudinal measures of variabil-
ity were also included because high
within-day variability might contribute
to longitudinal variability and thus pro-
vide greater power to detect an associ-
ation. These 6-month values were used
as predictors of progression of retinop-
athy, the annual values were used as
predictors of progression of nephropa-
thy, and the biennial values were used
as predictors of CAN.
The Supplementary Data includes
equations that deﬁne each measure, ex-
cept for the MAGE, for which there is no
single equation. The pooled within-day
variance was used in lieu of the mean of
the within-day SD, the variance being a
quadratic function of the SD.
Statistical Methods
During the DCCT, 37,058 quarterly visits
were conducted, from which 259,406
proﬁle values were expected; however,
42,209 (16.3%) were not collected. At
each of the seven time points, between
15 and 18% of glucose values were miss-
ing. Only 67% (24,866) of the quarterly
7-point proﬁles were complete, 15.3%
were missing a single time point, 5.4%
were missing between 2 and 6 time
points, and 12.2% were missing the
complete proﬁle (Supplementary Fig. 1).
However, the HbA1c data were virtually
complete.
To address the missing glucose data,
the statistical technique of multiple im-
putation (20,21) was used to provide
10 estimates of eachmissing value, yield-
ing 10 complete data sets. Multiple im-
putations were generated using chained
equations (MICE [22]) and themethod of
Schafer and Yucel (23). The results of the
twomethods were consistent, and those
using MICE are presented here. A given
analysis was then conducted using each
of the 10 complete data sets, and the
results were averaged using themethods
of Rubin and Schenker (24). For the anal-
ysis of each outcome, the resulting CI and
P value accounted for the overall extent
of the original missing data. A more thor-
ough description of these methods
is provided in the Supplementary Data,
which also includes a validation of the
multiple imputation approach for deal-
ing with missing values in the DCCT
data.
Baseline characteristics are described
using mean (SD) or frequency (%). The
discrete Cox proportional hazards re-
gression model (25), adjusted for tied
event times, assessed the effects of
measures of variation on relative risk
of a three-step progression of retinopa-
thy and the onset of microalbuminuria.
A logistic regression model for repeated
measures using generalized estimating
equations (26) assessed the effects of
covariates on the odds of CAN over 2,
4, 6, and 8 years of follow-up. Updated
values of each measure of variation
wereusedas a time-dependent covariate,
meaning that at a given point in time, the
most recent measure of the covariate
was used as the value of the covariate for
each subject at risk at that time. The 157
subjects with prevalent microalbuminuria
at baseline were excluded from analy-
ses of nephropathy, as were the 66 sub-
jects with prevalent CAN at baseline
who were excluded from the analyses
of CAN.
Analyses were performed using SAS
software (SAS Institute, Inc., Cary, NC)
and R software. Along with P values,
the test statistic Z value is presented to
represent the strength of the associa-
tion of the covariate with the outcome,
with absolute values of Z $ 1.96
representing a nominally signiﬁcant
P value # 0.05. The Holm procedure
was used to provide corrected levels of
signiﬁcance to account for the multiple
tests conducted in the analyses of all
outcomes (27).
The multiply imputed data sets used
as the basis for these analyses can be




Baseline characteristics of the DCCT
cohort have been presented pre-
viously (1) and are summarized in
Supplementary Table 1. The DCCT
cohort was evenly divided, by design,
into the primary prevention and sec-
ondary intervention cohorts, based
on the absence or presence of compli-
cations at baseline, respectively, with
average diabetes duration of 2.6 and
9 years, respectively. The mean age
was 27 years, slightly more than half
were men, and the mean HbA1c was
8.9%, with no difference between
treatment groups.
A summary of the distributions of the
measures of glycemia, glycemic variabil-
ity, and long-term variation at baseline,
at 1 year, and over follow-up are reported
in Table 1. The correlations among
the measures over all follow-up visits
are presented in Supplementary Table
2. No two measures of variation were
colinear or redundant, with all such
correlations #0.94. Correlations of
measures of variability with the mean
blood glucose ranged typically as high
as 0.73, except for the within-day and
the longitudinal mean M-value, with
correlations of 0.94 and 0.88 with the
mean within-day and longitudinal glu-
cose values, respectively.
Multiple measures of glucose vari-
ability were signiﬁcantly associated
with each of the three outcomes in anal-
yses that did not adjust for the mean
blood glucose or multiple tests of signif-
icance (Supplementary Table 3). In these
analyses, retinopathy progression was
nominally signiﬁcantly associated with
the within-day SD, M-value, and with all
of the longitudinal meanmeasures of var-
iability; the onset of microalbuminuria
with some of the within-day vari-
ance measures (SD and M-value), and
all of the longitudinal measures of var-
iability; and CAN with the MAGE,
M-value, and all of the measures of
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longitudinal variation. Many of these
remained statistically signiﬁcantwhen cor-
rected for the total of 24 statistical tests by
the Holm procedure (Supplementary
Table 3).
After adjusting for the within-day
mean blood glucose, no measure of
within-day variability remained nomi-
nally signiﬁcantly associated with any
of the three outcomes (Table 2). How-
ever, after adjusting for the longitudinal
mean blood glucose, the mean M-value
remained nominally signiﬁcantly associ-
ated with microalbuminuria, and the to-
tal and between-day variance with CAN
(Table 2).
Applying the Holm correction for
8 tests for a given complication would
require that the largest |Z| value
be $2.734 for signiﬁcance, two-sided,
at the 0.05 level; and that the second
largest be $2.69. Only the effect of
the longitudinal total variance on CAN
(Z = 3.03) and that of the longitudinal
M-value on microalbuminuria (Z =
4.23, P , 0.0001) meet this criterion.
The association of the between-day var-
iance with CAN does not meet the Holm
criterion (Z = 2.63 to ,2.69). Further,
applying the Holm procedure for the
complete set of 24 tests conducted in
aggregate for the three outcomes would
require a |Z| value $3.08 for signiﬁ-
cance. Only the association of the longi-
tudinal M-value with microalbuminuria
(Z = 4.23) meets this criterion.
Analyses were also conducted sepa-
rately within the DCCT intensive and con-
ventional groups that showed a like
paucity of signiﬁcant associations in
both groups when adjusted for the
corresponding measure of mean blood
glucose (within-proﬁle or longitudinally).
The Supplementary Data presents ad-
ditional analyses using the coefﬁcient
of variation (CV = SD/mean) that curi-
ously showed an inverse association
with retinopathy and microalbuminu-
ria. The Supplementary Data also pre-
sents statistical derivations which
show that an increasing coefﬁcient
of variation is a marker of decreasing
blood glucose, not increasing glycemic
variability.
CONCLUSIONS
The current analyses differ from previ-
ous analyses examining the potential ef-
fects of glycemic variability, independent
from mean glycemia, on complications
during the DCCT (8,10–12) by including
additional assessments of glycemic
Table 1—Measures of glycemia and glycemic variability in the DCCT cohort at baseline, at 1 year of follow-up, and over all
visits (N = 1,441); incident cases of retinopathy and microalbuminuria and prevalent cases of CAN over all visits
Baseline Year 1 All visits
Measure of average glucose,
median (quartiles 1, 3), rSD*
Within-day mean blood
glucose (mg/dL)
223.1 (172.2, 282.1) 177.1 (134.8, 231.5) 182.7 (139.7, 241.7)
81.5 71.7 75.6
Longitudinal mean of the proﬁle
mean glucose (mg/dL)
223.1 (172.2, 282.1) 183.4 (148.4, 232.3) 182.0 (149.1, 229.6)
81.5 62.2 59.7
Longitudinal mean HbA1c (%) 8.8 (7.9, 10.1) 7.6 (6.9, 8.9) 7.9 (7.0, 9.1)
1.6 1.5 1.6
Longitudinal mean HbA1c (mmol/mol) 72.7 (62.8, 86.9) 59.6 (51.9, 73.8) 62.8 (53.0, 76.0)
17.9 16.2 17.0
Measures of glucose variability,
median (quartiles 1, 3), rSD*
Within-day standard deviation (mg/dL) 77.2 (60.2, 98.7) 72.0 (52.6, 92.2) 74.6 (55.2, 97.7)
28.5 29.4 31.5
Within-day MAGE (mg/dL) 163.8 (117.0, 214.5) 143.0 (103.0, 201.5) 154.5 (109.0, 213.5)
72.3 73.0 77.5
Within-day M-value 96.9 (56.1, 154.5) 53.2 (27.1, 103.3) 61.68 (31.82, 114.3)
72.9 56.5 61.2
Longitudinal mean MAGE (mg/dL) 163.8 (117.0, 214.5) 150.4 (122.3, 183.3) 158.6 (133.4, 187.2)
72.3 45.2 39.9
Longitudinal mean M-value 96.9 (56.1,154.5) 58.3 (36.0, 97.9) 71.14 (45.64, 112.1)
72.9 45.9 49.3
Total variance† within and between
days (mg/dL)2
6,165.7 (3,770.6, 9,893.2) 6,093.9 (4,239.0, 8,709.4) 7,129.1 (4,902.4, 10,000.4)
4,538.7 3,314.0 3,779.2
Between-day variance† (mg/dL)2 d 1,465.1 (700.5, 3,013.9) 1,980.6 (1,040.7, 3,605.6)
1,714.9 1,901.3
Pooled within-day variance† (mg/dL)2 6,165.7 (3,770.6, 9,893.2) 5,694.5 (3,960.8, 7,983.8) 6,213.1 (4,491.4, 8,438.9)
4,538.7 2,982.2 2,926.3
Incident and prevalent outcomes‡
Retinopathy (N = 1,441), incidence, n (%) d d 271 (18.8)
Microalbuminuria (N = 1,284), incidence, n (%) d d 118 (9.2)
CAN (N = 1,375), prevalence at years 2, 4, 6,
and 8 (n) d d 49, 79, 60, 24
*All analyses of glucose-based values are based on multiply imputed data sets. Values for the quartiles of each measure are calculated using all
imputations. The SDs are calculated using Rubin’s variance formula (20) averaged over imputations (except for the longitudinal variances). †For the
longitudinal variances, the rSD is a robust estimator of the SD obtained as 0.74133 (quartile 32 quartile 1) from a randomly selected imputation.
‡Incident retinopathy: $3-step change on the ETDRS scale at a 6-month visit in the full cohort (N = 1,441); incident microalbuminuria: AER $30
mg/24 h on two successive annual visits among the 1,284 subjects with AER,30mg/24 h at baseline; prevalent CAN as described in RESEARCH DESIGNAND
METHODS among the 1,375 subjects without CAN at baseline.
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variability and more complete glucose
proﬁles through multiple imputation
methods. Although the prior analyses of
these data (8,10–12) also showed no as-
sociation of within-day measures of vari-
ability with long-term complications, they
suffered from the large fraction of incom-
plete quarterly proﬁles. The prior reports
used simple analyses in which there was
no attempt to correct for the large frac-
tion of missing glucose values other than
to eliminate subjects from the analysis
(10) or to compute proﬁle summary
measures from incomplete proﬁles
(8,11,12), which could have contributed
to reduced power to detect associations.
For example, prior reports simply com-
puted the SD and other measures from
the available values. This strategy intro-
duces errors into the estimates for each
proﬁle that in turn reduce power. For ex-
ample, if a preponderance of preprandial
values are missing, the within-day SD is
overestimated,whereas ifmorepostpran-
dial values are missing, the SD is under-
estimated.
Further, there was a modest correla-
tion, ranging up to 0.73, between mea-
sures of variability and themean glucose
level, except for the M-value, which
had a strong correlation of 0.94 that re-
ﬂects the glycemic exposure component
of this metric, and the mean M-value
with a correlation of 0.88 with the up-
dated mean blood glucose. Because the
within-day variance (or SD) is correlated
with the mean, the analysis adjusted for
the mean provides the more relevant
assessment of the role of glycemic vari-
ability. Thus, it was prespeciﬁed that
analyses of the effects of glycemic vari-
ability on outcomes would adjust for the
relevant measure of mean glycemia, ei-
ther the within-day mean blood glucose
for within-daymeasures of glycemic var-
iation or the updatedmean blood glucose
over time for longitudinalmeasures of be-
tween-day variation. However, unad-
justed and adjusted analyses for the
mean blood glucose are both presented.
In this report using multiply imputed
complete data sets in simple analyses
not adjusted for the mean level of blood
glucose, various measures of within-day
and longitudinal (average or between-
day) variability were associated with
each microvascular complication during
the DCCT (Supplementary Table 3).
However, after adjusting for the mean
glucose, few associations remained
nominally signiﬁcant. The longitudinal
mean M-value was strongly associated
with microalbuminuria (Z = 4.23) when
adjusted for the longitudinal mean glu-
cose (P, 0.0001), in part a reﬂection of
its high correlation with the longitudinal
mean blood glucose (r = 0.88). The total
variance and the between-day variance
were both associated with CAN, with
Z values of 3.03 (P = 0.0025) and 2.63
(P = 0.0087), respectively, when ad-
justed for the longitudinalmean glucose.
These associations with microalbuminuria
and CAN remained nominally signiﬁcant
when also adjusted for the mean HbA1c.
However, when also corrected for 24 total
tests using the Holm procedure (28), only
the adjusted longitudinal mean M-value
association with microalbuminuria
remained statistically signiﬁcant. Sepa-
rate analyses within the DCCT inten-
sive and conventional group produced
similarly negative results, as above,
within each group.
The major weakness of these data is
that the 7-point glucose proﬁles may be
Table 2—Association of measures of glucose variability over a mean of 6.5 years
of quarterly follow-up in the DCCT with progression of complications
Adjusted for mean blood glucose*
Hazard ratio 95% CL Z value P value†
Retinopathy
Within-day
SD 0.937 0.834, 1.054 21.08 0.28
MAGE 0.938 0.837, 1.050 21.11 0.27
M-value 0.804 0.582, 1.112 21.32 0.19
Longitudinal
Total blood glucose variance 0.951 0.844, 1.072 20.83 0.41
Between-day variance 0.920 0.839, 1.009 21.76 0.08
Within-day variance 0.970 0.872, 1.080 20.55 0.59
Mean MAGE 0.966 0.853, 1.095 20.54 0.60
Mean M-value 0.972 0.792, 1.191 20.28 0.79
Microalbuminuria
Within-day
SD 1.021 0.842, 1.238 0.21 0.84
MAGE 1.01 0.834, 1.213 0.062 0.96
M-value 0.899 0.517, 1.564 20.38 0.71
Longitudinal
Total blood glucose variance 1.084 0.838, 1.401 0.61 0.54
Between-day variance 1.132 0.999, 1.283 1.95 0.06
Within-day variance 0.904 0.698, 1.172 20.76 0.45
Mean MAGE 0.812 0.621, 1.062 21.52 0.13





SD 1.098 0.952, 1.268 1.29 0.20
MAGE 1.138 0.999, 1.298 1.93 0.06
M-value 1.336 0.953, 1.874 1.68 0.10
Longitudinal
Total blood glucose variance 1.357 1.114, 1.655 3.03 0.0025
Between-day variance 1.221 1.052, 1.416 2.63 0.0087
Within-day variance 1.132 0.946, 1.355 1.35 0.18
Mean MAGE 1.155 0.925, 1.444 1.27 0.21
Mean M-value 1.011 0.690, 1.483 0.06 0.96
*Models for the association of within-day measures of variation with the risk of progression of
microvascular complications are also adjusted for the within-day mean blood glucose; models
for longitudinal measures of variation are adjusted for the longitudinal mean level of blood
glucose. The hazard ratio is from a Cox proportional hazards model of the incidence of
retinopathy and nephropathy progression over time, and the odds ratio is from a general
estimating equation logistic regression model of prevalence of CANat 2, 4, 6, and 8 years of follow-
up.The association of all measures with progression of complications without adjustment for the
mean blood glucose is shown in the Supplementary Data. CL, conﬁdence limits.
†After applying the Holm procedure to correct for the total of 24 tests, only the effect of the
mean M-value on risk of microalbuminuria (Z = 4.23) meets the criteria for signiﬁcance at the 0.05
level.
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insufﬁcient to characterize glucose vari-
ability correctly when compared, for ex-
ample, with CGM. The M-value and
MAGE, in particular,wereoriginally devel-
oped for use with continuous data. One
study has reported thatmeasurements of
glucose variability from the 7-point glu-
cose proﬁle differed from those derived
from CGM (29). Further, it has been re-
ported that even one hyperglycemic spike
may cause continued overproduction of
reactive oxygen species for days in the
setting of subsequent normal glucose ho-
meostasis by activating a multicompo-
nent feedback loop (30). Thus, variability
in the 7-point glucose proﬁles may not
capture the full degree of variability that
would have been observed had CGM
been used. Of course, this assumes that
CGM is the gold standard to capture var-
iability, and that may not be the case.
Conversely, the large DCCT data sets
available with the longitudinal assess-
ment of diabetes complications, and
the careful implementation of modern
statistical analyses to address missing
glucose data, may offset this weakness.
We used multiple imputed complete
data sets that would correct the associ-
ation of measures of variation with out-
comes for any bias introduced by missing
data and should yield more deﬁnitive or
reliable results than an analysis based
only on the incomplete observed data.
Although proving that we have com-
pletely addressed the shortcomings of
prior analyses is not possible, the previ-
ously demonstrated lack of associations
of within-proﬁle and longitudinal mea-
sures of glycemic variability with out-
comes has largely been conﬁrmed.
We previously reported that the level
of HbA1c over time in the DCCT ex-
plained virtually all of the difference in
the risk of complications between the
intensive and conventional groups, but
that in the combined cohort, the HbA1c
as a risk factor for complications ex-
plained only ;10–15% of the variation
in risk (2–4). The results reported here
using blood glucose values show that
neither diurnal variation nor longitudi-
nal variation based on quarterly 7-point
proﬁles appears to contribute substan-
tial additional effects beyond those of
the mean blood glucose.
In summary, analyses that fully ac-
count for the missing and incomplete
blood glucose proﬁles and the inclusion
of additional measures of variability fail
to show that the within-day variability in
blood glucose, when adjusted for the
mean glucose, is associated with the de-
velopment or progression of retinopathy,
nephropathy, or CAN. Moreover, the lon-
gitudinal measures of variability are not
associated with the risk of complications
when adjusted for the mean glucose and
corrected for multiple tests, with the ex-
ception of the longitudinal M-value asso-
ciation with microalbuminuria. Overall,
the measures of glycemic variability
based on the complete quarterly 7-point
glucose proﬁle data sets fail to provide
strong or consistent evidence that glyce-
mic variability contributes to the risk of
development or progression of microvas-
cular complications beyond that contrib-
uted by the mean level of glucose.
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